Global Gorlin Syndrome Market - Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Upcoming Report
  • Oct 2019
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Gorlin Syndrome Market By Therapy Type (Topical Chemotherapy, Photodynamic Therapy), Treatment Type (Medication, Surgery), Drugs (Itraconazole, Vismodegib and Others), Route of Administration (Oral, Topical and Others), End- Users (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026

Market Analysis: Global Gorlin Syndrome Market

Global Gorlin syndrome market is expected to grow at a steady CAGR in the forecast period of 2019-2026. Increase in demand of targeted mode of therapies and high unmet need of treatment are the key factors for growth of this market

Market Definition: Global Gorlin Syndrome Market

Gorlin Syndrome is also known as nevoid basal cell carcinoma syndrome is rare genetic disorder that affects the skin, bones, brain and other organs. It is characterized by broad face, rib malformation and an extraordinary predisposition to basal cell carcinoma. It is caused by mutation in the PTCH1 gene which is a tumor suppressor gene. A defect of these genes underlies the signs and symptoms of Gorlin syndrome in people.

According to the statistics published in the U.S. Department of Health & Human Services, an estimated annual incidence population of basal cell carcinoma is more than one million in the United States and less than 1 percent of these skin cancers are related to Gorlin syndrome. Presence of refined healthcare infrastructure and high demand of disease specific novel therapies are the key factors that fueling the market growth

Market Drivers

  • The competitive scenario of market and strategic collaborations may boost the market position
  • Huge financial support to the researchers for developing novel intervention is boosting the market growth
  • High demand of disease specific novel treatment can also act as a market driver
  • High unmet need and emerging new market can drive the growth of this market

Market Restraints

  • The high cost diagnosis and treatment of disease and unfavorable reimbursement scenario are expected to limit market growth
  • Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market

Segmentation: Global Gorlin Syndrome Market

By Therapy Type

  • Topical Chemotherapy
  • Photodynamic Therapy

By Treatment

  • Medication
  • Surgery

By Drugs

  • Itraconazole
  • Vismodegib
  • Others

By Route of Administration

  • Oral
  • Topical
  • Others

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • South America

    • Brazil
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific

  • Middle East & Africa

    • South Africa
    • Rest of Middle East & Africa

Key Developments in the Market:

  • In April 2019, PellePharm, Inc has initiated multicenter pivotal phase III trial of Patidegib, a topical gel, hedgehog signaling pathway inhibitor for the treatment of Gorlin syndrome. If trial successful, it will significantly change the treatment landscape for patients suffering from Gorlin syndrome.
  • In December 2018, Mayne Pharma Group Limited has acquired the exclusive US right to develop, register and commercialize SUBA-itraconazole from HedgePath Pharmaceuticals, Inc for USD 5.00 million. SUBA-itraconazole was approved in the Europe for the treatment of Gorlin syndrome. The acquisition of SUBA-itraconazole, enables the company to accelerate the ability to address unmet needs for patients suffering from Gorlin syndrome

Competitive Analysis:

Global Gorlin syndrome market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global Gorlin syndrome market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global Gorlin syndrome market are LEO Pharma A/S, Mayne Pharma Group Limited, PellePharm, Inc, Novartis AG, Mylan N.V., Jubilant Life Sciences Ltd, Amneal Pharmaceuticals LLC, Alkem Labs, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd, Zydus Cadila, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc and others

Research Methodology: Global Gorlin Syndrome Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global Gorlin syndrome market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19